Neuropace
NPCE
112 hedge funds and large institutions have $422M invested in Neuropace in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 18 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
15% more capital inflows, than outflows
Capital inflows: $25.9M | Capital outflows: $22.6M
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
0.63% less ownership
Funds ownership: 78.59% → 77.95% (-0.63%)
1% less funds holding
Funds holding: 113 → 112 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Light Asset Management
Edina,
Minnesota
|
+$6.46M |
| 2 |
BlackRock
New York
|
+$2.11M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.89M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.66M |
| 5 |
HWM
HighMark Wealth Management
St. Paul,
Minnesota
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$9.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2M |
| 3 |
TCM
Topline Capital Management
Santa Monica,
California
|
-$1.06M |
| 4 |
Renaissance Technologies
New York
|
-$1.01M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$954K |
NPCE Hedge Fund Activity: Q2 2026 in Review
112 of the 8,362 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2026, worth a combined $422M — up 21% from $348M a quarter earlier.
Fund positioning in NPCE was balanced in Q2 2026: 18 funds opened new positions, 18 closed out, 48 added to existing stakes and 36 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $6.46M. The largest seller was OrbiMed, cutting an estimated $9.5M.
- 112 institutional investors held Neuropace (NPCE) as of Q2 2026, down from 113 in Q1 2026.
- Funds reported $422M of Neuropace stock for Q2 2026, up 21% quarter-over-quarter.
- 18 funds opened new Neuropace positions in Q2 2026 and 18 closed out, a net change of 0 holders.
- The largest Neuropace buyer in Q2 2026 was First Light Asset Management, an estimated $6.46M added.
- The largest Neuropace seller in Q2 2026 was OrbiMed, an estimated $9.5M sold.
Based on aggregated 13F filings for Q2 2026.